Clinical Impact of New Data From HIVR4P 2021 Virtual

January 27-28 and February 3-4, 2021
In this downloadable slideset, CCO’s expert faculty members summarize key studies from this important conference, including clinical data on new PrEP options, implementation strategies, multipurpose prevention technologies, and an emerging treatment.
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Kenneth Mayer, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 518 KB
Released: February 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

CCO commentary by Professor Don Smith on CROI 2021 data on ARV-associated weight gain and long-acting injectable ART

person default Don Smith, MD Released: April 20, 2021

Drs Monica Gandhi and Joseph Eron discuss next-line ART options for a heavily treatment-experienced patient with multiclass resistance .

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 19, 2021 Expired: April 18, 2022

Clinical Care Options (CCO) commentary by Dr Zhao Yan on data presented at CROI 2021 on the impact of the COVID-19 pandemic on HIV treatment

Dr. Zhao Yan Released: April 19, 2021

Download CCO slides reviewing data and guidelines on next-line ART for heavily-treatment experienced patients with HIV and multiclass drug resistance

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Released: April 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue